Codexis, Inc. 8-K Filing Summary
Business Context and Reporting Period
Codexis, Inc. filed a Current Report on Form 8-K on February 3, 2011, to announce financial results for the fourth quarter and the full year ended December 31, 2010. The filing includes a press release as Exhibit 99.1 detailing the company's performance.
Key Financial Metrics
- Annual Revenue: $107 million for the year ended December 31, 2010.
- Pharmaceutical Product Sales: Increased by 77% year-over-year.
- Other Metrics: The filing text does not provide specific values for profit, cash flow, margins, debt, or liquidity.
Material Changes
Annual revenue grew by 29% compared to the prior year. Pharmaceutical product sales saw a significant increase of 77%.
Guidance, Outlook, and Risks
The provided text does not contain specific forward-looking guidance, management commentary beyond the headline results, or detailed risk factors. The filing notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed quarterly breakdowns and segment performance.
- Confirm the specific drivers behind the 77% increase in pharmaceutical product sales.
- Review the company's 10-K for the year ended December 31, 2010, for comprehensive data on profitability, cash flow, and debt levels not included in this 8-K summary.